• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Keros Therapeutics, Inc. - common stock (NQ:KROS)

    11.02 +0.03 (+0.27%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Mar 13, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 516,561
    Open 11.02
    Bid (Size) 10.25 (200)
    Ask (Size) 15.21 (100)
    Prev. Close 10.99
    Today's Range 10.88 - 11.35
    52wk Range 9.120 - 22.55
    Shares Outstanding 23,337,862
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    KEROS THERAPEUTICS INC (NASDAQ:KROS) Posts Q4 2025 Earnings and Revenue Miss, Shares Decline ↗
    Via Chartmill
    News headline image
    Keros Therapeutics Inc (NASDAQ:KROS) Emerges as a High-Growth Momentum Breakout Candidate ↗
    Keros Therapeutics exemplifies a high-growth momentum strategy, combining explosive revenue growth, perfect technical ratings, and a defined breakout setup for potential entry. 
    Via Chartmill

    Performance

    YTD
    -40.6%
    -40.6%
    1 Month
    -35.3%
    -35.3%
    3 Month
    -48.8%
    -48.8%
    6 Month
    -29.5%
    -29.5%
    1 Year
    -3.9%
    -3.9%

    More News

    Read More
    News headline image
    Keros Therapeutics' Quiet Near-Term Outlook Overshadows Pipeline Potential: Analyst ↗
    Via Benzinga
    News headline image
    Keros Therapeutics Stops PAH Drug Development, Shrinks Workforce By 45% ↗
    Via Benzinga
    News headline image
    Deal Dispatch: Harley-Davidson To Wipe Out? Plus, Prada's Versace Purchase Garners A Fashionable Price ↗
    Via Benzinga
    News headline image
    Analyst Expectations For Keros Therapeutics's Future ↗
    Via Benzinga
    News headline image
    Deep Dive Into Keros Therapeutics Stock: Analyst Perspectives (11 Ratings) ↗
    Via Benzinga
    News headline image
    Where Keros Therapeutics Stands With Analysts ↗
    Via Benzinga
    News headline image
    Keros Therapeutics Goes Up For Sale On Heels Of Stockholder Rights Plan ↗
    Via Benzinga
    News headline image
    These stocks are gapping in today's session ↗
    Via Chartmill
    News headline image
    Keros Therapeutics Adopts Defense Strategy Against Potential Hostile Takeover, Explores Sale: Retail’s Overjoyed ↗
    Via Stocktwits
    News headline image
    Crude Oil Falls Over 4%; Keros Therapeutics Shares Jump ↗
    Via Benzinga
    News headline image
    PriceSmart Posts Better-Than-Expected Earnings, Joins Enact Holdings, DexCom And Other Big Stocks Moving Higher On Thursday ↗
    Via Benzinga
    News headline image
    12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
    Via Benzinga
    News headline image
    Forecasting The Future: 7 Analyst Projections For Keros Therapeutics ↗
    Via Benzinga
    News headline image
    KEROS ALERT: Bragar Eagel & Squire, P.C. is Investigating Keros Therapeutics, Inc. on Behalf of Keros Stockholders and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    News headline image
    Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Keros Therapeutics, Inc. (KROS)
    From Kirby McInerney LLP
    Via Business Wire
    News headline image
    Crude Oil Rises Sharply; JPMorgan Chase Earnings Top Views ↗
    Via Benzinga
    News headline image
    Nasdaq Surges Over 2%; Goldman Sachs Posts Upbeat Q4 Results ↗
    Via Benzinga
    News headline image
    Keros Therapeutics Stock Heads For Record Low After Dosing Halt In Pulmonary Disease Trial, Retail Buzz Spikes ↗
    Via Stocktwits
    News headline image
    Keros Therapeutics, Inc. Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your Rights - KROS
    Via ACCESSWIRE
    News headline image
    Shareholders that lost money on Keros Therapeutics, Inc.(KROS) should contact Levi & Korsinsky about Securities Fraud Investigation - KROS
    Via ACCESSWIRE
    News headline image
    Levi & Korsinsky Announces an Investigation on Behalf of Keros Therapeutics, Inc. (KROS) Shareholders Who May Have Been Affected by Fraud
    Via ACCESSWIRE
    News headline image
    12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
    Via Benzinga
    News headline image
    Dow Tumbles 200 Points; Liquidity Services Shares Spike Higher ↗
    Via Benzinga
    Topics Stocks

    Frequently Asked Questions

    Is Keros Therapeutics, Inc. - common stock publicly traded?
    Yes, Keros Therapeutics, Inc. - common stock is publicly traded.
    What exchange does Keros Therapeutics, Inc. - common stock trade on?
    Keros Therapeutics, Inc. - common stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Keros Therapeutics, Inc. - common stock?
    The ticker symbol for Keros Therapeutics, Inc. - common stock is KROS on the Nasdaq Stock Market
    What is the current price of Keros Therapeutics, Inc. - common stock?
    The current price of Keros Therapeutics, Inc. - common stock is 11.02
    When was Keros Therapeutics, Inc. - common stock last traded?
    The last trade of Keros Therapeutics, Inc. - common stock was at 03/13/26 04:00 PM ET
    What is the market capitalization of Keros Therapeutics, Inc. - common stock?
    The market capitalization of Keros Therapeutics, Inc. - common stock is 257.18M
    How many shares of Keros Therapeutics, Inc. - common stock are outstanding?
    Keros Therapeutics, Inc. - common stock has 257M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.